ストックスクリーナーアプリを入手
1.741
32.62%
0.421
前日終値:
$1.32
開ける：
$1.45
24時間の取引高:
1.33M
Relative Volume:
4.06
時価総額：
$125.96M
収益：
$69.56M
当期純損益:
$-240.05M
株価収益率:
-0.5902
EPS:
-2.95
ネットキャッシュフロー:
$-121.90M
1週間 パフォーマンス:
+37.84%
1か月 パフォーマンス:
+44.68%
6か月 パフォーマンス:
-33.94%
1年 パフォーマンス:
-56.67%
1日の値動き範囲:
$1.35
$1.797
1週間の範囲:
$1.225
$1.797
52週間の値動き範囲:
$1.05
$4.32
Adc Therapeutics Sa Stock (ADCT) Company Profile
ADCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.7594 | 125.96M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.75 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
534.70 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
263.14 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
222.79 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 開始されました | Guggenheim | Buy |
| 2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 開始されました | CapitalOne | Overweight |
| 2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-08-17 | 再開されました | Jefferies | Buy |
| 2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-09 | 開始されました | BofA/Merrill | Buy |
| 2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : ADC Therapeutics SA, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ADC Therapeutics Reports First Quarter 2025 Financial Results - TradingView
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ADC Therapeutics reports high response in lymphoma trial - Investing.com
Breakthrough: New Cancer Drug Combo ZYNLONTA-COLUMVI Achieves 90% Complete Response in Lymphoma Trial - Stock Titan
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Barclays PLC Purchases 13,756 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 - BioSpace
JPMorgan Chase & Co. Has $74,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday - Defense World
LPL Financial LLC Invests $50,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
BlackRock, Inc. Reduces Stake in ADC Therapeutics SA - GuruFocus
Geode Capital Management LLC Acquires 9,938 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data a - GuruFocus
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - BioSpace
Stock Market Recap: Adc Therapeutics SA (ADCT) Concludes at 1.41, a -5.37 Surge/Decline - DWinneX
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ADC Therapeutics Announces Preclinical Data Highlighted at the A - GuruFocus
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data at AACR 2025 | ADCT Stock News - GuruFocus
Russell Investments Group Ltd. Buys 9,248 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Seeking Alpha
Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com
Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter
Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Neuroendocrine tumors Pipeline Analysis and Clinical Trials - openPR.com
SEC Form PRE 14A filed by ADC Therapeutics SA - Quantisnow
HC Wainwright Lifts Earnings Estimates for ADC Therapeutics - MarketBeat
ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX
ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat
Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World
Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology
ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
ADC Therapeutics (NYSE:ADCT) Given New $7.00 Price Target at Guggenheim - MarketBeat
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Bradford Era
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
大文字化:
|
ボリューム (24 時間):